Celik, S. Et Al. 2022. Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey. UROLOGIA INTERNATIONALIS , vol.106, no.1 , 35-43.

Celik, S., KIZILAY, F., YÖRÜKOĞLU, K., ASLAN, G., Ozen, H., AKDOĞAN, B., ... Sozen, S.(2022). Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey. UROLOGIA INTERNATIONALIS , vol.106, no.1, 35-43.

Celik, Serdar Et Al. "Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey," UROLOGIA INTERNATIONALIS , vol.106, no.1, 35-43, 2022

Celik, Serdar Et Al. "Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey." UROLOGIA INTERNATIONALIS , vol.106, no.1, pp.35-43, 2022

Celik, S. Et Al. (2022) . "Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey." UROLOGIA INTERNATIONALIS , vol.106, no.1, pp.35-43.

@article{article, author={Serdar Celik Et Al. }, title={Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey}, journal={UROLOGIA INTERNATIONALIS}, year=2022, pages={35-43} }